Choreo LLC Lowers Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Choreo LLC cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 20.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,132 shares of the biotechnology company’s stock after selling 290 shares during the period. Choreo LLC’s holdings in United Therapeutics were worth $404,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Trust Point Inc. lifted its holdings in United Therapeutics by 45.5% during the 4th quarter. Trust Point Inc. now owns 1,697 shares of the biotechnology company’s stock worth $599,000 after buying an additional 531 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of United Therapeutics by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the biotechnology company’s stock valued at $3,340,000 after acquiring an additional 909 shares in the last quarter. Caprock Group LLC boosted its holdings in United Therapeutics by 16.3% in the fourth quarter. Caprock Group LLC now owns 792 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 111 shares during the period. Mediolanum International Funds Ltd grew its stake in United Therapeutics by 8.7% during the 4th quarter. Mediolanum International Funds Ltd now owns 5,221 shares of the biotechnology company’s stock worth $1,863,000 after purchasing an additional 417 shares in the last quarter. Finally, EMC Capital Management increased its holdings in United Therapeutics by 9.5% during the 4th quarter. EMC Capital Management now owns 1,577 shares of the biotechnology company’s stock worth $556,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock worth $44,516,965 in the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 4.9 %

Shares of NASDAQ UTHR opened at $370.74 on Thursday. The stock has a market cap of $16.55 billion, a P/E ratio of 16.28, a P/E/G ratio of 0.92 and a beta of 0.57. The stock has a 50 day moving average of $361.99 and a two-hundred day moving average of $358.32. United Therapeutics Co. has a twelve month low of $211.61 and a twelve month high of $417.82.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.